The honest conversation about antidepressants I wish my psychiatrist had with me
The debate surrounding antidepressants and their long-term use is a complex and often emotionally charged topic. Many individuals who have been taking antidepressants or anti-anxiety medications for years find themselves grappling with a myriad of questions. Are they still necessary? How would they know if they didn't take them? Is it wise to stay on them indefinitely, or is there a case to be made for discontinuing them? These questions are not just philosophical but also deeply medical and personal.
In this article, we delve into the insights of Awais Aftab, a psychiatry professor at Case Western Reserve University School of Medicine, who offers a nuanced perspective on these very questions. Aftab's work, particularly his newsletter, Psychiatry at the Margins, and his piece in the New York Times, highlights the need for honest and transparent conversations about antidepressants, free from the exploitation by political figures like RFK Jr. and the MAHA movement.
The Ambivalence of Antidepressants
Aftab argues that the ambivalence surrounding antidepressants is a natural consequence of the increasing control we have over aspects of our lives, such as mood and emotional reactivity, through medical progress. This control, however, comes with genuine tradeoffs and uncertainties. The philosopher Bill Fulford's idea that scientific progress creates new choices, which in turn bring the full diversity of human values into play, explains why more choices lead to more uncertainty and ambivalence.
"We can choose to take antidepressants or not, continue them or stop them, but we can’t choose not to have the choice. And the uncertainty is genuine," Aftab says. The questions of whether the drugs are helping and whether they are still necessary are not always easy to answer for any specific person.
However, Aftab points out that too few clinicians are attuned to this complexity. Most psychiatrists are not trained to explore the meaning and emotions patients assign to their medications. Patients may feel relieved by symptom improvement but simultaneously detest the feeling of dependence on a pill. They may credit the drug with saving their life and still wonder who they would be without it. When clinicians fail to anticipate and directly address this ambivalence, patients are left to navigate it alone.
Navigating the Decision to Discontinue Medication
When faced with the question of whether to continue or discontinue medication, Aftab recommends the courage to make an informed choice. The decision should be based on multiple factors, including the patient's mental health history and the subjective meaning of the medication. Some patients may be at peace with taking a daily medication, while others may find it gnaws at them.
For those who want to stop their meds, Aftab emphasizes the importance of doing so carefully, with clinical help and a slow taper. A cautious taper would take several months, and it often requires using doses that are not available in standard pills, which can be challenging and expensive. There is also no consensus in the psychiatric field on the best tapering protocols, leading to confusion and misinformation online.
Physical and Psychological Dependence
Physical dependence on antidepressants is a well-established phenomenon. The body adapts to the presence of the drug, and when the dose is reduced or stopped, withdrawal symptoms can occur, such as dizziness, nausea, "brain zaps," vertigo, irritability, insomnia, and a rebound of anxiety or mood symptoms. Most people on long-term antidepressants will experience some degree of withdrawal, although severe withdrawal is less common.
Psychological dependence, on the other hand, is more about the anxiety of going without the medication. Once the idea that the pill is necessary to feel okay has been internalized, it can feel impossible to stop. This psychological dependence should not be ignored by clinicians, and any distorted worries and fears should be addressed.
The confusion between physical dependence and addiction is understandable. While addiction involves compulsive use despite harmful consequences, quickly escalating doses, craving, and loss of control, antidepressants do not produce these behaviors. However, they can produce physiological dependence, where the body adapts to the drug's presence and reacts when it is removed.
The Research Gap and the Role of Critics
Aftab highlights the slow pace of research into withdrawal struggles within the psychiatric establishment. Part of this is due to funding issues, with federal research funding heavily tilted toward basic neuroscience and drug development, at the expense of studying the everyday clinical realities of medication use and tapering. This has led to a lack of high-quality randomized controlled trials comparing specific tapering methods.
Additionally, there is an ideological dismissiveness towards withdrawal, with some prominent psychiatrists downplaying its significance. This has been damaging, as patients who experience severe withdrawal have been told it's just their depression coming back or that their symptoms aren't real. Clinicians, trained to see medications as solutions, struggle to recognize them as sources of harm.
To address this research gap, Aftab suggests making research into iatrogenic harm a funding priority, developing better measurement tools, running proper tapering trials, updating clinical guidelines, and training clinicians to take deprescribing as seriously as prescribing. He expresses concern about the MAHA movement and RFK Jr.'s stance on antidepressants, fearing that their political agenda and funding decisions will lead to confusion, distrust, stigma, polarization, and possibly restricted access to medications for those who need them.
